1. Home
  2. SLNO
  3. SLNO News

Latest Soleno Therapeutics Inc. (SLNO) News on August 23, 2025

TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy
SLNO

Insider Monkey

2 months ago

TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference
SLNO

GlobeNewswire

2 months ago

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference

DoorDash, AMD upgraded: Wall Street's top analyst calls
SLNO

The Fly

2 months ago

DoorDash, AMD upgraded: Wall Street's top analyst calls

SLNO

MT Newswires

2 months ago

TD Cowen Initiates Soleno Therapeutics at Buy With $110 Price Target

Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
SLNO

Insider Monkey

2 months ago

Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects

Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
SLNO

GlobeNewswire

2 months ago

Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference

High Growth Tech Stocks in US for June 2025
SLNO

Simply Wall St.

2 months ago

High Growth Tech Stocks in US for June 2025

EMA validates Soleno’s application for Prader-Willi syndrome treatment
SLNO

Pharmaceutical Technology

3 months ago

EMA validates Soleno’s application for Prader-Willi syndrome treatment

Soleno Therapeutics seeking regulatory approval in treatment of PWS
SLNO

TipRanks

3 months ago

Soleno Therapeutics seeking regulatory approval in treatment of PWS

SLNO

MT Newswires

3 months ago

Sector Update: Health Care Stocks Flat to Lower Pre-Bell Friday

SLNO

MT Newswires

3 months ago

Soleno Application for Hyperphagia Treatment in Patients with Prader-Willi Syndrome Gets European Validation

Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR
SLNO

Insider Monkey

3 months ago

Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR

Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
SLNO

GlobeNewswire

3 months ago

Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome

Soleno Therapeutics to Participate in Upcoming June Conferences
SLNO

GlobeNewswire

3 months ago

Soleno Therapeutics to Participate in Upcoming June Conferences

Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome
SLNO

GlobeNewswire

3 months ago

Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025
SLNO

GlobeNewswire

3 months ago

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025
SLNO

GlobeNewswire

3 months ago

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025

Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now?
SLNO

Insider Monkey

3 months ago

Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now?

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025
SLNO

GlobeNewswire

3 months ago

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025

SLNO

GuruFocus.com

4 months ago

Soleno Therapeutics Inc (SLNO) Q1 2025 Earnings Call Highlights: Navigating Early Success and ...

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
SLNO

GlobeNewswire

4 months ago

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable
SLNO

Zacks

4 months ago

Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable

Exploring High Growth Tech Stocks In The US Market
SLNO

Simply Wall St.

4 months ago

Exploring High Growth Tech Stocks In The US Market

Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET
SLNO

GlobeNewswire

4 months ago

Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

Soleno Therapeutics Announces VYKAT(TM) XR Launch
SLNO

GlobeNewswire

4 months ago

Soleno Therapeutics Announces VYKAT(TM) XR Launch

SLNO

MT Newswires

5 months ago

Soleno Therapeutics Insider Sold Shares Worth $265,156, According to a Recent SEC Filing

High Growth Tech Stocks To Watch In The US April 2025
SLNO

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In The US April 2025

SLNO

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 04/01/2025

SLNO

MT Newswires

5 months ago

Soleno Therapeutics Insider Sold Shares Worth $10,709,353, According to a Recent SEC Filing

SLNO

MT Newswires

5 months ago

Soleno Therapeutics Insider Sold Shares Worth $1,013,627, According to a Recent SEC Filing

SLNO

MT Newswires

5 months ago

Soleno Therapeutics Insider Sold Shares Worth $6,376,789, According to a Recent SEC Filing

SLNO

MT Newswires

5 months ago

Soleno Therapeutics Insider Sold Shares Worth $3,044,343, According to a Recent SEC Filing

Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?
SLNO

Insider Monkey

5 months ago

Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?

Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday?
SLNO

Insider Monkey

5 months ago

Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday?

Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday?
SLNO

Insider Monkey

5 months ago

Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday?

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower
SLNO

Investor's Business Daily

5 months ago

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower

Tiny Drugmaker Soars on FDA Win to Treat Never-Ending Hunger
SLNO

Bloomberg

5 months ago

Tiny Drugmaker Soars on FDA Win to Treat Never-Ending Hunger

Soleno wins FDA approval for Prader-Willi hyperphagia treatment
SLNO

Pharmaceutical Technology

5 months ago

Soleno wins FDA approval for Prader-Willi hyperphagia treatment

Soleno stock skyrockets on FDA drug approval
SLNO

Yahoo Finance Video

5 months ago

Soleno stock skyrockets on FDA drug approval

SLNO

MT Newswires

5 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Thursday

SLNO

MT Newswires

5 months ago

Sector Update: Health Care

SLNO

MT Newswires

5 months ago

Top Premarket Gainers

SLNO

MT Newswires

5 months ago

Update: Soleno Therapeutics Secures FDA Approval for Hyperphagia Treatment; Shares Surge Premarket

SLNO

MT Newswires

5 months ago

Soleno Therapeutics Secures FDA Approval for Drug to Treat Hyperphagia

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
SLNO

GlobeNewswire

5 months ago

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

First Prader-Willi drug to reduce hunger approved by FDA
SLNO

BioPharma Dive

5 months ago

First Prader-Willi drug to reduce hunger approved by FDA

Exploring US High Growth Tech Stocks In March 2025
SLNO

Simply Wall St.

6 months ago

Exploring US High Growth Tech Stocks In March 2025

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
SLNO

GlobeNewswire

6 months ago

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Soleno Therapeutics to Participate in Upcoming February Investor Conferences
SLNO

GlobeNewswire

7 months ago

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

High Growth Tech Stocks to Watch in January 2025
SLNO

Simply Wall St.

7 months ago

High Growth Tech Stocks to Watch in January 2025

Is Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential?
SLNO

Insider Monkey

7 months ago

Is Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential?

Soleno Therapeutics, Inc. (NASDAQ:SLNO): When Will It Breakeven?
SLNO

Simply Wall St.

8 months ago

Soleno Therapeutics, Inc. (NASDAQ:SLNO): When Will It Breakeven?

SLNO

MT Newswires

8 months ago

Soleno Therapeutics Gets $200 Million Debt Financing From Oxford Finance

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
SLNO

GlobeNewswire

8 months ago

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

High Growth Tech Stocks to Watch in November 2024
SLNO

Simply Wall St.

9 months ago

High Growth Tech Stocks to Watch in November 2024

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
SLNO

GlobeNewswire

9 months ago

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

FDA delays decision of Soleno’s Prader-Willi syndrome drug
SLNO

Pharmaceutical Technology

9 months ago

FDA delays decision of Soleno’s Prader-Willi syndrome drug

Kronos, Idorsia plan layoffs; PTC shelves ALS drug
SLNO

BioPharma Dive

9 months ago

Kronos, Idorsia plan layoffs; PTC shelves ALS drug

Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment
SLNO

GuruFocus.com

9 months ago

Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment

SLNO

MT Newswires

9 months ago

Soleno Therapeutics Says FDA Extends DCCR NDA Review Citing 'Major Amendment'

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
SLNO

GlobeNewswire

9 months ago

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
SLNO

GlobeNewswire

9 months ago

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
SLNO

Simply Wall St.

9 months ago

Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
SLNO

GlobeNewswire

10 months ago

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Soleno Therapeutics to Participate in Upcoming November Investor Conferences
SLNO

GlobeNewswire

10 months ago

Soleno Therapeutics to Participate in Upcoming November Investor Conferences

Lamb Weston, Adecoagro, and More Stocks See Action From Activist Investors
SLNO

Barrons.com

10 months ago

Lamb Weston, Adecoagro, and More Stocks See Action From Activist Investors

Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
SLNO

GlobeNewswire

10 months ago

Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.

TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors
SLNO

Barrons.com

10 months ago

TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors

Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR
SLNO

Insider Monkey

10 months ago

Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR

Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment
SLNO

Insider Monkey

10 months ago

Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment

Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc.
SLNO

GuruFocus.com

10 months ago

Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc.

SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
SLNO

Zacks

10 months ago

SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA

Why Soleno Therapeutics Stock Blasted 9% Higher Today
SLNO

Motley Fool

10 months ago

Why Soleno Therapeutics Stock Blasted 9% Higher Today

SLNO

MT Newswires

10 months ago

Soleno Therapeutics Says US FDA Determines NDA for DCCR Does Not Need Advisory Panel Meeting for Now

Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
SLNO

GlobeNewswire

a year ago

Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

SLNO

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/04/2024

SLNO

MT Newswires

a year ago

Soleno Therapeutics Insider Sold Shares Worth $1,069,306, According to a Recent SEC Filing

Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc
SLNO

GuruFocus.com

a year ago

Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc

High Growth Tech Stocks To Watch In The United States
SLNO

Simply Wall St.

a year ago

High Growth Tech Stocks To Watch In The United States

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
SLNO

GlobeNewswire

a year ago

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc.
SLNO

GuruFocus.com

a year ago

Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc.

SLNO

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 09/03/2024

SLNO

MT Newswires

a year ago

HC Wainwright Initiates Soleno Therapeutics at Buy

High Growth Tech Stocks To Watch In September 2024
SLNO

Simply Wall St.

a year ago

High Growth Tech Stocks To Watch In September 2024

SLNO

MT Newswires

a year ago

Soleno Therapeutics Insider Sold Shares Worth $5,454,707, According to a Recent SEC Filing

Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
SLNO

Zacks

a year ago

Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review

Soleno wins FDA priority review for Prader-Willi therapy
SLNO

Pharmaceutical Technology

a year ago

Soleno wins FDA priority review for Prader-Willi therapy

Soleno Therapeutics, Inc. (SLNO): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
SLNO

Insider Monkey

a year ago

Soleno Therapeutics, Inc. (SLNO): One of Oppenheimer’s Top Stock Picks For the Next 12 Months

SLNO

MT Newswires

a year ago

Soleno Therapeutics Says FDA Accepts Application for Prader-Willi Syndrome Drug

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
SLNO

GlobeNewswire

a year ago

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SLNO

GlobeNewswire

a year ago

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SLNO

MT Newswires

a year ago

Soleno Therapeutics Chairman Ernest Mario Stepping Down

Soleno Therapeutics Announces Updates to its Board of Directors
SLNO

GlobeNewswire

a year ago

Soleno Therapeutics Announces Updates to its Board of Directors

SLNO

MT Newswires

a year ago

Oppenheimer Adjusts Soleno Therapeutics' PT to $65 From $59, Maintains Outperform Rating

SLNO

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 08/08/2024

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
SLNO

GlobeNewswire

a year ago

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

When Can We Expect A Profit From Soleno Therapeutics, Inc. (NASDAQ:SLNO)?
SLNO

Simply Wall St.

a year ago

When Can We Expect A Profit From Soleno Therapeutics, Inc. (NASDAQ:SLNO)?

These Stock Winners Are ‘Strong Buys’ With More Room Left to Run
SLNO

TipRanks

a year ago

These Stock Winners Are ‘Strong Buys’ With More Room Left to Run

SLNO

MT Newswires

a year ago

Soleno Therapeutics Submits New Drug Application to FDA for Prader-Willi Syndrome Treatment

Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
SLNO

GlobeNewswire

a year ago

Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Share on Social Networks: